Embecta (EMBC) Competitors $19.82 -0.17 (-0.85%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends EMBC vs. AXNX, NVCR, NVST, NARI, IRTC, LIVN, ENOV, WRBY, CNMD, and TNDMShould you be buying Embecta stock or one of its competitors? The main competitors of Embecta include Axonics (AXNX), NovoCure (NVCR), Envista (NVST), Inari Medical (NARI), iRhythm Technologies (IRTC), LivaNova (LIVN), Enovis (ENOV), Warby Parker (WRBY), CONMED (CNMD), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry. Embecta vs. Axonics NovoCure Envista Inari Medical iRhythm Technologies LivaNova Enovis Warby Parker CONMED Tandem Diabetes Care Axonics (NASDAQ:AXNX) and Embecta (NASDAQ:EMBC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk. Do institutionals & insiders believe in AXNX or EMBC? 99.5% of Axonics shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 1.9% of Axonics shares are held by insiders. Comparatively, 0.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend AXNX or EMBC? Axonics currently has a consensus target price of $71.00, suggesting a potential upside of 0.03%. Embecta has a consensus target price of $23.00, suggesting a potential upside of 16.04%. Given Embecta's stronger consensus rating and higher possible upside, analysts plainly believe Embecta is more favorable than Axonics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axonics 0 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Embecta 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is AXNX or EMBC more profitable? Embecta has a net margin of 6.97% compared to Axonics' net margin of -1.31%. Axonics' return on equity of 0.36% beat Embecta's return on equity.Company Net Margins Return on Equity Return on Assets Axonics-1.31% 0.36% 0.31% Embecta 6.97%-18.54%11.43% Does the media favor AXNX or EMBC? In the previous week, Embecta had 6 more articles in the media than Axonics. MarketBeat recorded 7 mentions for Embecta and 1 mentions for Axonics. Embecta's average media sentiment score of 0.95 beat Axonics' score of 0.00 indicating that Embecta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axonics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Embecta 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, AXNX or EMBC? Axonics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Embecta has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Does the MarketBeat Community favor AXNX or EMBC? Axonics received 173 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 66.41% of users gave Axonics an outperform vote while only 6.25% of users gave Embecta an outperform vote. CompanyUnderperformOutperformAxonicsOutperform Votes17466.41% Underperform Votes8833.59% EmbectaOutperform Votes16.25%Underperform Votes1593.75% Which has higher earnings and valuation, AXNX or EMBC? Embecta has higher revenue and earnings than Axonics. Axonics is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxonics$366.38M9.90-$6.09M-$0.12-591.45Embecta$1.12B1.03$78.30M$1.3514.68 SummaryEmbecta beats Axonics on 12 of the 18 factors compared between the two stocks. Ad Porter & CompanyHiding in the Bible New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.This is the untold, true story of God’s Investment. Get Embecta News Delivered to You Automatically Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EMBC vs. The Competition Export to ExcelMetricEmbectaSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15B$4.41B$5.19B$9.32BDividend Yield3.05%44.87%4.78%4.06%P/E Ratio14.6825.33128.2217.54Price / Sales1.0346.521,259.00139.66Price / Cash5.9744.2041.2237.95Price / Book-1.557.254.884.92Net Income$78.30M$13.83M$119.69M$225.78M7 Day Performance-0.50%-2.91%16.64%-1.56%1 Month Performance37.45%3.03%16.32%6.68%1 Year Performance12.68%47.13%35.37%22.48% Embecta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EMBCEmbecta4.1041 of 5 stars$19.82-0.9%$23.00+16.0%+14.2%$1.15B$1.12B14.682,200Short Interest ↓AXNXAxonics1.1641 of 5 stars$70.98+0.8%$71.00+0.0%+21.8%$3.63B$366.38M-591.45610High Trading VolumeNVCRNovoCure2.87 of 5 stars$32.91-1.5%$32.67-0.7%+136.7%$3.56B$577.74M-23.861,453NVSTEnvista3.621 of 5 stars$19.56+0.5%$20.65+5.6%-19.3%$3.37B$2.50B-2.5112,800Positive NewsNARIInari Medical2.5692 of 5 stars$55.67+0.1%$58.89+5.8%-13.5%$3.26B$574.50M-41.181,300Analyst ForecastIRTCiRhythm Technologies2.8808 of 5 stars$90.08+4.2%$107.82+19.7%-9.5%$2.82B$492.68M-17.782,000LIVNLivaNova3.9507 of 5 stars$50.01-2.9%$69.17+38.3%-0.3%$2.72B$1.24B122.622,900Analyst UpgradePositive NewsENOVEnovis3.1146 of 5 stars$46.91+1.7%$67.00+42.8%-14.9%$2.62B$2.00B-21.396,550Positive NewsWRBYWarby Parker1.6817 of 5 stars$24.22+2.5%$20.73-14.4%+106.2%$2.46B$669.77M-87.523,491Analyst ForecastCNMDCONMED4.6148 of 5 stars$71.74-1.1%$79.80+11.2%-37.1%$2.22B$1.29B17.234,000Positive NewsTNDMTandem Diabetes Care4.6431 of 5 stars$33.26+1.8%$53.81+61.8%+19.6%$2.18B$747.72M-16.922,400Positive News Related Companies and Tools Related Companies AXNX Alternatives NVCR Alternatives NVST Alternatives NARI Alternatives IRTC Alternatives LIVN Alternatives ENOV Alternatives WRBY Alternatives CNMD Alternatives TNDM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EMBC) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EMBC Stock Alerts